A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

NCT05945368 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

78

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Eribulin mesylate injection、Pertuzumab、Trastuzumab

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University